Ro Body GLP-1 Growth Engine

Ro Body turned Ro from a transactional telehealth seller into a chronic care operator with much higher revenue per patient. Erectile dysfunction visits could be handled as a quick consult plus generic prescription, but obesity treatment required monthly follow up, lab work, dose changes, side effect management, and refill coordination. That let Ro layer a $145 monthly care subscription on top of drug revenue and use its lab, pharmacy, and home testing stack much more intensively, driving an estimated $370M of GLP-1 revenue in 2024 and roughly 40% of company revenue by year end.

• The operational jump matters as much as the market size jump. Ro built obesity care on assets like Workpath, Kit, Modern Fertility, its own lab, and six owned pharmacies, so a patient can do intake, complete labs, get prescribed, adjust dosage, and receive medication through one workflow instead of piecing together doctors, tests, and pharmacies.
  2 sacra 3 sacra
• Ro Body also changed the competitive set. Roman mainly competed with other generic men’s health clinics on price and marketing, while obesity pulled Ro into competition with Noom on coaching led weight loss programs and with Virta on structured metabolic care sold around outcomes, not just convenience.
  1 sacra 4 sacra 5 sacra
• The economics improved because GLP-1 care is more durable than ED. Ro estimated GLP-1 related sales tripled from January 2023 to August 2024, while average transaction value rose from about $93 to $134. Unlike ED generics, GLP-1 treatment is designed to continue for long periods and needs active dose management, which supports higher retention and lifetime value.
  2 sacra

The next phase is turning Ro Body from a fast growing consumer product into obesity infrastructure. As branded GLP-1 access becomes more standardized, the durable advantage shifts to who can manage longitudinal care best, prove outcomes, and become the preferred front end for drug makers, employers, and payers entering the category.